- Home
- PPBT vs IMCC Comparison
PPBT vs IMCC Comparison
Compare PPBT & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- IMCC
- Stock Information
- Founded
- PPBT 2010
- IMCC 1980
- Country
- PPBT Israel
- IMCC Israel
- Employees
- PPBT N/A
- IMCC N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- PPBT Health Care
- IMCC Health Care
- Exchange
- PPBT Nasdaq
- IMCC Nasdaq
- Market Cap
- PPBT 7.1M
- IMCC 7.5M
- IPO Year
- PPBT N/A
- IMCC N/A
- Fundamental
- Price
- PPBT $2.65
- IMCC $1.57
- Analyst Decision
- PPBT Strong Buy
- IMCC
- Analyst Count
- PPBT 1
- IMCC 0
- Target Price
- PPBT $33.00
- IMCC N/A
- AVG Volume (30 Days)
- PPBT 12.3K
- IMCC 8.3K
- Earning Date
- PPBT 03-10-2025
- IMCC 03-31-2025
- Dividend Yield
- PPBT N/A
- IMCC N/A
- EPS Growth
- PPBT N/A
- IMCC N/A
- EPS
- PPBT N/A
- IMCC N/A
- Revenue
- PPBT N/A
- IMCC $37,551,778.00
- Revenue This Year
- PPBT N/A
- IMCC $22.59
- Revenue Next Year
- PPBT N/A
- IMCC $32.86
- P/E Ratio
- PPBT N/A
- IMCC N/A
- Revenue Growth
- PPBT N/A
- IMCC 10.71
- 52 Week Low
- PPBT $2.00
- IMCC $1.50
- 52 Week High
- PPBT $20.60
- IMCC $8.10
- Technical
- Relative Strength Index (RSI)
- PPBT 40.91
- IMCC 36.37
- Support Level
- PPBT $2.64
- IMCC $1.50
- Resistance Level
- PPBT $2.93
- IMCC $1.84
- Average True Range (ATR)
- PPBT 0.15
- IMCC 0.14
- MACD
- PPBT 0.02
- IMCC -0.01
- Stochastic Oscillator
- PPBT 2.46
- IMCC 14.29
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.